State of Wyoming Purchases 15,057 Shares of Indivior PLC $INDV

State of Wyoming lifted its position in shares of Indivior PLC (NASDAQ:INDV) by 201.2% in the third quarter, HoldingsChannel.com reports. The firm owned 22,539 shares of the company’s stock after purchasing an additional 15,057 shares during the period. State of Wyoming’s holdings in Indivior were worth $543,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Principal Financial Group Inc. bought a new position in Indivior during the 3rd quarter valued at approximately $1,696,000. Arizona State Retirement System purchased a new stake in Indivior in the third quarter worth $712,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Indivior by 201.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,550 shares of the company’s stock valued at $351,000 after acquiring an additional 9,730 shares in the last quarter. Federated Hermes Inc. purchased a new position in Indivior during the 3rd quarter valued at $8,120,000. Finally, Y Intercept Hong Kong Ltd lifted its position in shares of Indivior by 104.4% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 52,007 shares of the company’s stock worth $1,254,000 after purchasing an additional 26,564 shares during the period. 60.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on INDV shares. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research report on Friday, October 31st. Finally, Northland Securities set a $50.00 target price on shares of Indivior in a research report on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.33.

Indivior Trading Up 1.3%

Indivior stock opened at $35.45 on Wednesday. The stock has a fifty day simple moving average of $34.93 and a two-hundred day simple moving average of $28.28. Indivior PLC has a 12 month low of $7.62 and a 12 month high of $38.00. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 38.53 and a beta of 0.80.

Insider Activity

In other Indivior news, Director Keith Humphreys purchased 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director directly owned 5,802 shares of the company’s stock, valued at $205,332.78. The trade was a 15.42% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel A. Ninivaggi purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. This trade represents a 4.80% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 4,871 shares of company stock worth $172,385.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.